LLY
Price
$711.48
Change
+$1.66 (+0.23%)
Updated
Aug 22, 04:59 PM (EDT)
Capitalization
637.99B
69 days until earnings call
NVS
Price
$126.94
Change
+$0.12 (+0.09%)
Updated
Aug 22, 04:59 PM (EDT)
Capitalization
245.42B
67 days until earnings call
Interact to see
Advertisement

LLY vs NVS

Header iconLLY vs NVS Comparison
Open Charts LLY vs NVSBanner chart's image
Eli Lilly & Co
Price$711.48
Change+$1.66 (+0.23%)
Volume$18.25K
Capitalization637.99B
Novartis AG
Price$126.94
Change+$0.12 (+0.09%)
Volume$26.92K
Capitalization245.42B
LLY vs NVS Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
LLY vs. NVS commentary
Aug 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Buy and NVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2025
Stock price -- (LLY: $711.68 vs. NVS: $126.98)
Brand notoriety: LLY: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: LLY: 69% vs. NVS: 81%
Market capitalization -- LLY: $637.99B vs. NVS: $245.42B
LLY [@Pharmaceuticals: Major] is valued at $637.99B. NVS’s [@Pharmaceuticals: Major] market capitalization is $245.42B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $637.99B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LLY’s FA Score shows that 1 FA rating(s) are green whileNVS’s FA Score has 2 green FA rating(s).

  • LLY’s FA Score: 1 green, 4 red.
  • NVS’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than LLY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LLY’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).

  • LLY’s TA Score: 6 bullish, 4 bearish.
  • NVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, LLY is a better buy in the short-term than NVS.

Price Growth

LLY (@Pharmaceuticals: Major) experienced а +1.49% price change this week, while NVS (@Pharmaceuticals: Major) price change was +2.23% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.13%. For the same industry, the average monthly price growth was +4.23%, and the average quarterly price growth was +14.02%.

Reported Earning Dates

LLY is expected to report earnings on Oct 30, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+2.13% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LLY($638B) has a higher market cap than NVS($245B). LLY has higher P/E ratio than NVS: LLY (46.52) vs NVS (18.51). NVS YTD gains are higher at: 35.188 vs. LLY (-7.262). NVS has higher annual earnings (EBITDA): 22.7B vs. LLY (19.7B). NVS has more cash in the bank: 7B vs. LLY (3.55B). NVS has less debt than LLY: NVS (32.6B) vs LLY (39.9B). NVS (55.2B) and LLY (53.3B) have equivalent revenues.
LLYNVSLLY / NVS
Capitalization638B245B260%
EBITDA19.7B22.7B87%
Gain YTD-7.26235.188-21%
P/E Ratio46.5218.51251%
Revenue53.3B55.2B97%
Total Cash3.55B7B51%
Total Debt39.9B32.6B122%
FUNDAMENTALS RATINGS
LLY vs NVS: Fundamental Ratings
LLY
NVS
OUTLOOK RATING
1..100
1123
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
2613
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6344
P/E GROWTH RATING
1..100
9680
SEASONALITY SCORE
1..100
44n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (75). This means that NVS’s stock grew somewhat faster than LLY’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is in the same range as LLY (26). This means that NVS’s stock grew similarly to LLY’s over the last 12 months.

NVS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as LLY (100). This means that NVS’s stock grew similarly to LLY’s over the last 12 months.

NVS's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as LLY (63). This means that NVS’s stock grew similarly to LLY’s over the last 12 months.

NVS's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as LLY (96). This means that NVS’s stock grew similarly to LLY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LLYNVS
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
39%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
38%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
53%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
54%
Bullish Trend 2 days ago
45%
Advances
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 3 days ago
49%
Declines
ODDS (%)
Bearish Trend 15 days ago
52%
Bearish Trend 17 days ago
45%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
45%
Aroon
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
33%
View a ticker or compare two or three
Interact to see
Advertisement
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PXI42.691.02
+2.44%
Invesco Dorsey Wright Energy MomentumETF
IWP141.652.40
+1.72%
iShares Russell Mid-Cap Growth ETF
PLDR34.850.55
+1.60%
Putnam Sustainable Leaders ETF
MAYU29.960.38
+1.30%
AllianzIM US Equity Buffer15 Unc May ETF
BSL14.170.07
+0.49%
Blackstone Senior Floating Rate 2027 Term Fund

LLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, LLY has been loosely correlated with NVS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LLY
1D Price
Change %
LLY100%
+0.26%
NVS - LLY
42%
Loosely correlated
+0.13%
AZN - LLY
40%
Loosely correlated
+0.63%
OGN - LLY
35%
Loosely correlated
+1.62%
MRK - LLY
33%
Loosely correlated
+1.50%
PFE - LLY
32%
Poorly correlated
+0.54%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.13%
GSK - NVS
67%
Closely correlated
+0.27%
AZN - NVS
60%
Loosely correlated
+0.63%
PFE - NVS
57%
Loosely correlated
+0.54%
JNJ - NVS
55%
Loosely correlated
+0.20%
SNY - NVS
49%
Loosely correlated
+1.46%
More